In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Specific reversal agents for NOACs: Initial experience and future outlook

EHRA webinar

Add to calendar22/09/201518:00 22/09/201519:00 Europe/Paris Specific reversal agents for NOACs: Initial experience and future outlook European Heart Rhythm Association contact@escardio.org DD/MM/YYYY
Stroke
Cardiovascular Pharmacology and Pharmacotherapy
Atrial Fibrillation

 

Focus on

By attending this Webinar, the participants will understand:

  • The management strategies that are currently available to manage bleeding events or urgent surgery in patients treated with NOACs
  • The clinical situations for which specific reversal agents to the NOACs may be useful and learn the advantages of such therapy as opposed to reversal strategies using unspecific haemostatic agents
  • The development and characteristics of idarucizumab, the specific reversal agent for dabigatran, of andexanet for the factor Xa inhibitors apixaban,  rivaroxaban and edoxaban, and LWMH, and of aripazine or PER977 for both thrombin and factor Xa inhibitors
  • The results of pre-clinical studies investigating the use of NOACs in different bleeding models
  • How healthy volunteer studies have demonstrated the immediate, complete, and sustained reversal of NOAC-induced anticoagulation by one of the specific antidotes
  • How RE-VERSE AD, the patient study of idarucizumab in dabigatran-treated patients and ANNEXA, the patient study of andexanet in Xa inhibitor treated patients, may demonstrate the clinical value of the specific reversal strategy

Join Prof. Menno Huisman, Prof. Oliver Grottke and Dr. Jan Steffel for this EHRA webinar. This programme includes case based presentations, online assessments and discussions with these key opinion leaders and will give you some useful tips for your daily clinical practice.

Watch the webinar recording

 

speakers

Menno Huisman Professor Menno Huisman (speaker)

Thrombosis And Hemostasis

Leiden University Medical Center 

Netherlands

Prof Oliver Grottke (speaker)

Dept Anesthesiology

Rwth University Hospital Aachen

Germany 

Jan Steffel Dr  Jan Steffel (host)

Co-chair, Electrophysiology and Pacing

University Hospital Zurich

Switzerland

Session information

Target audience : This webinar addresses EHRA members and cardiologists working in the field of arrhythmias.

During the webinar, you will be able to send your questions by chat and interact with our key opinion leaders who will provide feedback live.

How to access the live webinar?

Upon registration, you will receive a confirmation email with the connection details. Please check your spam if you do not receive any email or contact us.

 This programme is supported by Boehringer Ingelheim in the form of an unrestricted educational grant. The scientific programme has not been influenced in any way by its sponsor.

Technical settings

The webinar is available on PC and Tablets. The use of smartphone is not recommended. For the best viewing experience, a high speed Internet connection is recommended (minimum 2Mbps). Please make sure that the firewall does not prevent the connection to the webinar.